DSDavid G. Silverman

David G. Silverman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David G. Silverman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Total Reversal of ALS Confirmed by EMG Normalization, Structural Reconstitution, and Neuromuscular–Molecular Restoration Achieved Through Computerized Brain-Guided Reengineering of the 1927 Nobel Prize Fever Therapy: A Case Report

    by M. Marc Abreu, Mohammad Hosseine-Farid, David G. Silverman

    Background: Neurological disorders are the leading cause of disability, affecting over three billion people worldwide. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring lost function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT2). This fully noninvasive treatment, delivered through an FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize-recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT2 induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins, which are known to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman was diagnosed with progressive ALS at the Mayo Clinic, with electromyography (EMG) demonstrating fibrillation and fasciculation indicative of denervation corroborated by neurological and MRI findings; the patient was informed that she had an expected survival of three to five years. A neurologist from Northwestern University confirmed the diagnosis and thus maintained the patient on FDA-approved ALS drugs (riluzole and edaravone). Her condition rapidly worsened despite pharmacological treatment, and she underwent CBIT2, resulting in (i) electrophysiological reversal with complete disappearance of denervation; (ii) biomarker correction, including reductions in neurofilament and homocysteine, IL-10 normalization (previously linked to mortality), and robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; (iv) reconstitution of tongue structure; and (v) return to complex motor tasks, including golf, pickleball, and swimming. Discussion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation, which induces heat shock response and upregulates heat shock proteins, resulting in the patient no longer meeting diagnostic criteria for ALS and discontinuation of ALS-specific medications. Beyond ALS, shared protein-misfolding pathology suggests that CBIT2 may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing this Nobel Prize-recognized therapeutic principle with computerized precision, CBIT2 establishes a framework for large-scale clinical trials. A century after fever therapy restored lost brain function and so decisively reversed dementia paralytica such that it earned the 1927 Nobel Prize in Medicine, CBIT2 now safely harnesses the therapeutic power of fever through noninvasive, intelligent, brain-guided thermal modulation. Amid a global brain health crisis, fever-based therapies may offer a path to preserve thought, memory, movement, and independence for the more than one-third of humanity currently affected by neurological disorders.

  • Open Access

    Total Reversal of ALS Confirmed by EMG Normalization and Neuromuscular–Molecular Evidence Achieved Through Computerized Brain-Guided Reengineering of the 1927 Nobel Prize Fever Therapy: A Video-Documented Case Report

    by M Marc Abreu, Mohammad Hosseini Farid, David G Silverman

    Background: Neurological disorders are the leading cause of disability, affecting over three billion people. Amyotrophic lateral sclerosis (ALS) is among the most feared and uniformly fatal neurodegenerative diseases, with no therapy capable of restoring function. Methods: We report the first application of therapeutic fever to ALS using Computerized Brain-Guided Intelligent Thermofebrile Therapy (CBIT²). This fully noninvasive treatment, delivered through FDA-approved computerized platform, digitally reengineers the 1927 Nobel Prize–recognized malarial fever therapy into a modern treatment guided by the Brain–Eyelid Thermoregulatory Tunnel. CBIT² induces therapeutic fever through synchronized hypothalamic feedback, activating heat shock proteins to restore proteostasis and neuronal function. Case presentation: A 56-year-old woman with rapidly progressive ALS was diagnosed at the Mayo Clinic, based on electromyography showing denervation and fasciculations corroborated by neurological and MRI findings; and patient was informed of an expected 3–5-year survival. Northwestern University independently confirmed the diagnosis and maintained her on FDA-approved ALS drugs (riluzole and edaravone). Her condition worsened and she underwent CBIT², resulting in: (i) electrophysiological reversal with disappearance of denervation and fasciculations; (ii) biomarker correction, including reductions in neurofilament and homocysteine, besides IL-10 normalization (previously linked to mortality) alongside robust HSP70 induction; (iii) restoration of gait, swallowing, respiration, speech, and cognition; and (iv) return to complex motor tasks, including golf and pickleball. Discussion/Conclusion: This case provides the first documented evidence that ALS can be reversed through digitally reengineered fever therapy aligned with thermoregulation. Beyond ALS, shared protein-misfolding pathology suggests CBIT² may extend to Alzheimer’s, Parkinson’s, and related disorders. By modernizing a Nobel Prize–recognized therapeutic principle with digital precision, CBIT² establishes a framework for large-scale clinical trials. Just as fever therapy a century ago restored lost brain function in dementia paralytica and earned the 1927 Nobel Prize, CBIT² now safely harnesses the therapeutic power of fever through brain-guided modulation. Amid a global brain health crisis, where neurological disorders affect more than three billion people, fever-based therapies may provide a path to preserve thought, memory, movement, and independence for over one third of humanity.

  • Integrated Assessment and Consultation for the Preoperative Patient

    by David G. Silverman, Stanley H. Rosenbaum


  • Rofecoxib does not compromise platelet aggregation during anesthesia and surgery

    by David G. Silverman, Thomas Halaszynski, Raymond Sinatra, Martha Luther, Christine S. Binder

    This study was undertaken because, although there is evidence that cyclooxygenase type 2 (COX)-2 inhibitors do not compromise platelets in healthy volunteers, many clinicians remain hesitant to administer them perioperatively without definitive evidence of intact platelet function during anesthesia and surgery. In 20 patients scheduled for lower abdominal and pelvic surgery, 5 mL of blood were obtained for baseline platelet aggregometry. One hour prior to surgery, patients received an oral solution of either rofecoxib (ROF) 50 mg or placebo (PLAC) by randomized, double-blinded assignment. Approximately one hour after onset of anesthesia, an intraoperative blood sample was obtained. Baseline and postdrug samples were centrifuged to generate platelet-rich plasma, which was challenged with adenosine diphosphate (ADP) and arachidonic acid (AA). Aggregometry was performed with and without incubation with aspirin. The data in each subject were normalized to baseline aggregation in response to AA alone and ADP alone. Intergroup differences were assessed using paired t test; P < 0.05 was considered significant. Consistent with known effects of anesthesia on platelet function, both groups had approximately 25% intraoperative declines in aggregation in response to ADP (P = NS for PLACvs ROF) and even greater declines in response to AA (P = NS for PLACvs ROF). Aspirin eliminated aggregation in response to AA in both groups (P = NS), and it caused similar declines in PLAC and ROF groups during exposure to ADP (P = NS). This study provides strong evidence that ROF does not compromise platelet aggregation during anesthesia and surgery; nor does it interfere with the platelet inhibitory effect of aspirin. Nous avons réalisé la présente étude parce que, même s’il y a une évidence que les inhibiteurs de la cyclo-oxygénase de type 2 (C0X)-2 n’altèrent pas les plaquettes chez des volontaires en bonne santé, de nombreux cliniciens hésitent encore à les administrer en période périopératoire sans avoir la preuve irréfutable de la conservation de la fonction plaquettaire pendant l’anesthésie et la chirurgie. Nous avons prélevé 5 mL de sang, pour une agrégométrie plaquettaire de base, chez 20 patients devant subir une opération pelvienne et abdominale basse. Une heure avant l’opération, une solution orale de 50 mg de rofécoxib (ROF) ou d’un placebo (PLAC) ont été administrés de façon aléatoire et en double insu. Une heure environ après le début de l’anesthésie, un échantillon de sang a été prélevé. Les échantillons de base et les prélèvements suivant la médication ont été centrifugés pour générer un plasma riche en plaquettes, lequel a été stimulé avec de l’adénosine diphosphate (ADP) et de l’acide arachidonique (AA). Lagrégométrie a été réalisée avec et sans incubation avec aspirine. Les données sur chaque sujet ont été normalisées à partir de l’agrégation de base en réaction à l’AA seule et l’ADP seule. Les différences intergroupes ont été évaluées par le test t pour des paires d’échantillons;P < 0,05 était considéré comme significatif. Conformément aux effets connus de l’anesthésie sur la fonction plaquettaire, il y a eu dans les deux groupes environ 25 % de diminution peropératoire de l’agrégation en réaction à l’ADP (P = NS pour le PLAC vs ROF) et une baisse encore plus grande en réaction à l’AA (P = NS pour le PLAC vs ROF). Laspirine a éliminé l’agrégation en réaction à l’AA dans les deux groupes (P = NS) et a causé une diminution similaire dans les groupes PLAC et ROF pendant l’exposition à l’ADP (P = NS). Létude fournit une indication claire que la ROF n’altère pas l’agrégation plaquettaire pendant l’anesthésie et la chirurgie; elle ne nuit pas non plus à l’effet inhibiteur de l’aspirine.


  • Effect of Rofecoxib on Platelet Aggregation in the Context of Anesthesia and Surgery

    by Thomas M. Halaszynski, David G. Silverman, Raymond S. Sinatra, Martha A. Luther, Christine S. Rinder